{"disease":{"id":"radioactive-iodine-refractory-differentiated-thyroid-cancer-with-nras-mutation","name":"radioactive iodine refractory differentiated thyroid cancer with nras mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06970353","title":"Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fudan University","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}